2 Weeks on Wegovy: What Most People Notice First

Your first injection is in the past, and the second is due. Here's where most people are at this point.

You've done the hardest part: decided to start, gone through the clinical assessment, and given yourself that first injection. Now you're in the in-between, past the beginning, nowhere near the milestones you've read about, and possibly wondering whether this is going to be worth it. That feeling is completely understandable, and it's one of the questions our prescribers hear from patients almost every week.

At two weeks, you're most likely still on the 0.25 mg dose. Wegovy's prescribing schedule begins there deliberately: semaglutide activates GLP-1 receptors involved in appetite signalling and the rate at which food leaves your stomach, and ramping up too quickly dramatically increases the chance of nausea and vomiting. The 0.25 mg pen's job is to settle your system into the mechanism gently. It is not the dose that drives the meaningful weight results seen in clinical trials.

Most people notice two things in this window: some degree of gastrointestinal discomfort (nausea, reflux, looser stools, or a general sense of queasiness shortly after injecting) and a subtle but real shift in appetite. Portions that felt ordinary a fortnight ago may now feel like too much. You might leave food on the plate without consciously trying to. These are signs the medicine is active, even if the scales haven't moved. For a fuller picture of how Wegovy works as a treatment, our overview page covers the mechanism in detail.

The side effects that hit hardest in week one and two, and what tends to ease off

Gastrointestinal side effects are the most commonly reported experience in the first two weeks. In the STEP 1 trial (a 68-week study of semaglutide 2.4 mg published in the New England Journal of Medicine) nausea was the most frequent side effect, concentrated around dose initiation and each increase. Vomiting, constipation, diarrhoea, indigestion and burping are all listed in the Wegovy patient information leaflet as common reactions.

The practical pattern for most people: nausea is worst in the 24–48 hours after injecting and tends to taper off as the week progresses. Eating smaller meals, avoiding rich or fatty food, and not lying down immediately after eating can reduce it. Fatigue is also common early on, often linked to eating less without realising it or to the body adjusting to the appetite suppression. Headaches appear for some.

What tends to ease off: nausea usually becomes less severe with each successive weekly dose once your system has adjusted at a given level. It typically spikes again when the dose increases, which is why the titration schedule exists. If nausea at two weeks is still disruptive or you're struggling to keep fluids down, contact your prescriber rather than pushing through. You can also report unexpected symptoms via the MHRA Yellow Card scheme, which exists precisely to capture real-world experience with medicines.

Rarely but importantly: severe, persistent stomach pain that radiates to the back requires urgent medical attention and should not be attributed to ordinary Wegovy nausea.

Weight loss at two weeks: what the evidence actually says

The honest answer is that two weeks is too short a window to draw conclusions. In clinical trials, participants using semaglutide achieved an average weight reduction of around 15% over 68 weeks, but that figure accumulated across more than a year of dose increases, lifestyle support, and maintained treatment. At the 0.25 mg starting dose, two weeks in, measurable scale movement is minimal for most people. Some see a small change; others see none. Both outcomes are consistent with the medicine working as intended.

There is, though, one early signal worth tracking: appetite. If you're physically hungry less often, if you feel full faster, or if your interest in food has shifted, that is the mechanism operating. For context on what happens if two weeks have passed with no change at all on the scales, our page on Wegovy with no weight loss at two weeks goes into that specifically.

The broader trajectory matters more than any single fortnight. People who do well on Wegovy long-term tend to be those who keep expectations anchored to the clinical evidence rather than week-by-week fluctuations. Understanding what's ahead helps: by four weeks, the first dose period ends and a prescriber review typically follows; by six weeks, many people are into the 0.5 mg phase and appetite changes are more pronounced. You can also read about what's common at eight weeks for a longer view.

What to actually do in week two, and who to contact if something doesn't feel right

Week two is mostly about consistency. Inject on your scheduled day, keep the pen refrigerated as your patient information leaflet instructs, and rotate the injection site. Track what you're eating, not obsessively, but enough to notice whether appetite really has shifted. Protein and hydration matter more than usual when you're eating less; a prescriber or dietitian can advise on specifics for your situation.

If you started through a private prescribing service, make sure you know how to reach them. At nume, aftercare is available seven days a week, the detail of how we're set up is on our about us page. If you're curious about what Wegovy costs privately and what those fees typically cover, our Wegovy cost page lays that out plainly.

Wegovy is a prescription-only medicine and every element of the dosing schedule (when to increase, whether to pause, whether to switch) belongs to your prescriber, not to anything you've read online. Two weeks in, the main job is staying the course and staying in contact with your clinical team. If you haven't yet started treatment and are considering it, you can start a free consultation with our prescribers to see whether Wegovy is clinically appropriate for you.